Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity
Antonella M. D’Ascanio, Jamie Mullally, William H. Frishman
Cardiology in Review (2023) Vol. 32, Iss. 1, pp. 83-90
Closed Access | Times Cited: 13

Showing 13 citing articles:

Comparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic Review
Jay Prakash Patel, Daksh Hardaswani, Jay Patel, et al.
Cureus (2025)
Open Access | Times Cited: 1
Newer pharmacological interventions directed at gut hormones for obesity
Michael Camilleri, Andrés Acosta
British Journal of Pharmacology (2023) Vol. 181, Iss. 8, pp. 1153-1164
Closed Access | Times Cited: 14
Bariatric Metabolic Surgery Instead of or In Addition to Obesity Pharmacotherapy: Perspectives on the Evolving and Emerging Concept of a Medical Bypass
Maria Lange, Sushuma Kalidindi
Obesity Surgery (2025)
Closed Access
Glucagon-like peptide-1 receptor agonists to improve cardiorenal outcomes: data from FLOW and beyond
Labib Imran Faruque, Kevin Yau, David Z.I. Cherney
Current Opinion in Nephrology & Hypertension (2025)
Closed Access
Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review
Abdullah Al Lawati, Ayman Alhabsi, R. Rahul, et al.
Diseases (2025) Vol. 13, Iss. 5, pp. 129-129
Open Access
Hippocampal Leptin Resistance and Cognitive Decline: Mechanisms, Therapeutic Strategies and Clinical Implications
Ismael Valladolid‐Acebes
Biomedicines (2024) Vol. 12, Iss. 11, pp. 2422-2422
Open Access | Times Cited: 3
Breaking down silos: the multifaceted nature of obesity and the future of weight management
Faith Anne N. Heeren, Valerie L. Darcey, Sarah E. Deemer, et al.
Philosophical Transactions of the Royal Society B Biological Sciences (2023) Vol. 378, Iss. 1885
Closed Access | Times Cited: 8
Amylin analogs for the treatment of obesity without diabetes: present and future
Theodoros Panou, Evanthia Gouveri, Djordje S. Popovic, et al.
Expert Review of Clinical Pharmacology (2024)
Closed Access | Times Cited: 2
GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity
Daria Abasheva, Alberto Ortíz, Beatriz Fernández‐Fernández
Clinical Kidney Journal (2024) Vol. 17, Iss. Supplement_2, pp. 19-35
Open Access | Times Cited: 2
Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy
Michał Nicze, Adrianna Dec, Maciej Borówka, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8202-8202
Open Access | Times Cited: 1
Obesity Medications and Their Impact on Cardiovascular Health: A Narrative Review
Kazi Nazrul Islam, Rahib K Islam, Victoria T Tong, et al.
Cureus (2024)
Open Access | Times Cited: 1
Incretin impact on gastric function in obesity: physiology, and pharmacological, surgical and endoscopic treatments
Michael Camilleri
The Journal of Physiology (2024)
Closed Access
Rare variants of the glucagon-like peptide-1 receptor (GLP1R) gene are overrepresented in a severe obesity cohort and associated with type 2 diabetes in the UK Biobank
Dale Handley, Sumaya Almansoori, Mitra S. Sato, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Page 1

Scroll to top